Trending at Lumira Ventures

Fusion Pharmaceuticals Announces IND Clearance For FPI-2068, A Jointly Developed Novel Targeted Alpha Therapy

Alyssia Watkin Portfolio News, Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the clearance of investigational new drug (IND) applications for [225Ac]-FPI-2068 (FPI-2068) and corresponding imaging analogue [111In]-FPI-2107 (FPI-2107) to the U.S. Food …

Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets

Alyssia Watkin Portfolio News, BioTheryX

Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced it has entered into a Research Collaboration and License agreement with Incyte to …

OpSens Announces 1,000th SavvyWire Procedure

Alyssia Watkin Portfolio News, Opsens

OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, announced a significant milestone for the Company as the SavvyWire has been successfully used by physicians in 1,000 procedures. The SavvyWire is …

Rare Disease Day 2023

Alyssia Watkin Lumira News, Congruence Therapeutics

Today, February 28th, 2023, is Rare Disease Day. Celebrated internationally, the day is an opportunity to raise awareness and advocate for rare diseases as a human rights priority and work towards a more inclusive society. Over 300 million people globally …

XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina

Alyssia Watkin Portfolio News, Xylocor Therapeutics

No serious adverse events related to drug product were reportedPatients demonstrated improvements in exercise capacity and reductions in episodes of chest painCardiac imaging results provide mechanistic evidence supporting the therapeutic potential of XC001 in cardiovascular disease XyloCor Therapeutics, a clinical-stage …

Cyrano Therapeutics Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of CYR-064 to Treat Post-Viral Smell Loss (Hyposmia)

Alyssia Watkin Portfolio News, Cyrano Therapeutics, Main Page

Currently no FDA-approved therapy for this serious condition Initiation of Phase 2 clinical trial expected to occur in Q2 2023 Cyrano Therapeutics, a biopharmaceutical company developing medicines for patients with hyposmia (smell loss), announced today that the U.S. Food and …

Deka Biosciences, Inc Announces Submission of Investigational New Drug (IND) Application for Lead Oncology Asset, DK210 (EGFR)

Alyssia Watkin Portfolio News, Deka BioSciences

Important Regulatory Milestone Provides Runway to Move DK210 (EGFR) into the Clinical Phase GERMANTOWN, Md., Dec. 27, 2022 /PRNewswire/ — Today, Deka Biosciences, Inc. (Deka), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced the submission …